Rezdiffra (Resmetirom) Vaccine Interaction Profile: What Women Need to Know

What Is Resmetirom and Why Are Women Taking It?

Resmetirom targets the thyroid hormone receptor beta isoform in the liver, the receptor responsible for hepatic fat oxidation and cholesterol metabolism. It works without the cardiac and bone side effects of systemic thyroid hormone excess because THR-β is predominantly expressed in the liver rather than the heart.

The FDA approved resmetirom (Rezdiffra) on March 14, 2024 for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and moderate-to-advanced liver fibrosis (stages F2 and F3). This makes it the first approved pharmacotherapy specifically for MASH.

Women are not a minority patient group for this drug. They are a central one.

Why MASH Disproportionately Affects Women After Midlife

Estrogen suppresses hepatic lipogenesis and promotes fatty acid oxidation. When estrogen declines during perimenopause, visceral fat accumulates and hepatic triglyceride content rises. A 2023 analysis published in Hepatology found that post-menopausal women have significantly higher rates of advanced fibrosis in MASH compared with pre-menopausal women of similar BMI and metabolic profile. The hormonal shift, not just diet or BMI, drives the trajectory.

Women with polycystic ovary syndrome (PCOS) face a parallel risk earlier in life. Insulin resistance and androgen excess in PCOS promote hepatic fat deposition, and PCOS is independently associated with a 2- to 3-fold higher prevalence of NAFLD/MASH compared with BMI-matched controls. Thyroid dysfunction, which is more common in women, compounds this risk further because the liver's lipid metabolism depends on adequate THR-β signaling.

Resmetirom's THR-β selectivity therefore addresses a pathway that is specifically disrupted in women with menopause-related or PCOS-related hepatic steatosis. That biological relevance is why understanding its full interaction profile, including vaccines, matters for the women who are most likely to take it.

Does Resmetirom Interact with Vaccines?

No direct pharmacokinetic or pharmacodynamic interaction between resmetirom and any licensed vaccine has been identified in published literature or in the Rezdiffra prescribing information as of mid-2025. The prescribing label does not list any vaccine-specific warnings. This is both reassuring and a reflection of a genuine evidence gap.

How Resmetirom Is Metabolized (and Why It Matters for Vaccines)

Resmetirom is primarily metabolized by CYP2C8 and, to a lesser extent, CYP3A4, with additional glucuronidation via UGT1A3. Vaccines are not metabolized by cytochrome P450 enzymes. An mRNA vaccine, a protein subunit vaccine, or an inactivated whole-pathogen vaccine generates an immune response through antigen presentation, not hepatic enzymatic transformation. There is therefore no classical pharmacokinetic pathway by which resmetirom and a vaccine could interfere with each other's primary mechanism.

The theoretical concern that does exist is subtler. Resmetirom, by modulating THR-β in the liver, alters hepatic gene expression including genes involved in complement activation and acute-phase protein synthesis. Whether this modulation meaningfully changes the magnitude or durability of vaccine-induced immune responses is simply not known. No immunogenicity sub-study was embedded in the key MAESTRO-NASH trial, and no post-marketing immunogenicity data are available as of this writing.

Inactivated and mRNA Vaccines: Current Position

For inactivated vaccines (influenza, hepatitis A, hepatitis B, pneumococcal polysaccharide and conjugate, HPV, recombinant shingles/Shingrix) and mRNA vaccines (COVID-19), there is no pharmacological basis for interaction with resmetirom. These vaccines do not rely on hepatic CYP enzymes for efficacy, and resmetirom is not immunosuppressive. Women on resmetirom should follow standard CDC adult immunization schedules without modification based on this drug alone.

Hepatitis B vaccination deserves particular mention. Women with MASH who have not been vaccinated against hepatitis B are at elevated risk of accelerated liver disease if they acquire HBV. The ACOG Committee on Immunization recommends that clinicians assess vaccination status at every preventive care visit. Starting resmetirom is an ideal prompt to confirm hepatitis A, hepatitis B, and pneumococcal coverage.

Live-Attenuated Vaccines: A Theoretical Caution Worth Naming

Live-attenuated vaccines, including varicella, MMR (measles-mumps-rubella), yellow fever, and the oral typhoid vaccine, contain replication-competent pathogens. They are contraindicated in patients on confirmed immunosuppressants. Resmetirom is not an immunosuppressant. However, because THR-β signaling in the liver influences innate immune gene networks and because no formal immunocompetence testing has been done in resmetirom-treated patients, some clinicians apply a precautionary preference for completing live-attenuated vaccines before starting resmetirom where scheduling allows. This is not a label recommendation; it is a clinical judgment call in the absence of data.

If a live-attenuated vaccine is needed urgently (for example, yellow fever vaccination required for travel that cannot be delayed), the decision should be made jointly between the prescribing hepatologist or obesity medicine specialist and an infectious disease or travel medicine clinician. No published guidance exists on this specific scenario.

Practical vaccine framework for women on resmetirom:

| Vaccine type | Examples | Current position on resmetirom | |---|---|---| | Inactivated / killed | Flu (IM), hepatitis A, hepatitis B | No interaction expected; follow standard schedule | | Subunit / recombinant | Shingrix, Gardasil 9, Pneu-conjugate | No interaction expected; follow standard schedule | | mRNA | COVID-19 (Pfizer, Moderna) | No interaction expected; follow standard schedule | | Live-attenuated | MMR, varicella, yellow fever, oral typhoid | No contraindication stated; discuss timing with prescriber if elective |

Can You Drink Alcohol While Taking Rezdiffra?

No. The clinical recommendation is zero alcohol while taking resmetirom. This is not a pharmacokinetic interaction in the traditional sense. Alcohol does not inhibit or induce CYP2C8 meaningfully. The problem is biological and is disease-based, not drug-based.

MASH is fundamentally a condition of hepatic injury and inflammation. Alcohol, even in moderate amounts, directly worsens hepatic steatosis, drives hepatocyte apoptosis via oxidative stress, and accelerates fibrosis progression. The MAESTRO-NASH trial excluded heavy drinkers from enrollment, meaning the efficacy and safety data for resmetirom were generated in patients with low or no alcohol intake. Using resmetirom while drinking regularly adds a second hepatotoxic input to an already injured liver, undermining the purpose of the drug.

The Rezdiffra prescribing information does not use the words "contraindicated with alcohol," but the clinical standard of care for MASH universally advises alcohol abstinence. Any hepatology or obesity medicine practice managing MASH will include alcohol cessation as a non-negotiable component of care alongside pharmacotherapy.

Women metabolize alcohol differently than men. Lower average body water content and lower alcohol dehydrogenase activity in gastric mucosa mean that women reach higher peak blood alcohol concentrations per gram of alcohol consumed. Women also progress to alcohol-related liver disease faster and at lower cumulative doses. This sex-specific vulnerability is directly relevant when counseling women with MASH on this point.

Drug-Drug Interactions Women on Resmetirom Should Know

CYP2C8 Inhibitors and Inducers

Resmetirom's metabolism by CYP2C8 means that strong CYP2C8 inhibitors can increase resmetirom plasma exposure. Gemfibrozil, a fibrate used for hypertriglyceridemia, is a potent CYP2C8 inhibitor and is listed as contraindicated with resmetirom in the prescribing label. Women with MASH commonly have combined dyslipidemia and may be candidates for fibrate therapy. Gemfibrozil must be avoided. Other fibrates (fenofibrate) do not carry the same prohibition.

Strong CYP2C8 inducers may reduce resmetirom exposure, though no dose adjustment is currently specified in the label.

Statins and OATP1B1/1B3 Transporters

Resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters, which affects the clearance of several statins. Simvastatin, atorvastatin, rosuvastatin, and pravastatin are all OATP substrates. The prescribing label limits simvastatin to 20 mg daily and atorvastatin to 40 mg daily when co-administered with resmetirom 100 mg. Women with MASH frequently have concurrent hyperlipidemia and are often on statin therapy. Statin dose review is mandatory when starting resmetirom.

Oral Contraceptives

Resmetirom lowers LDL cholesterol and affects thyroid hormone-binding globulin (TBG) levels. Combined oral contraceptives (COCs) raise TBG, which could influence free thyroid hormone levels in women whose thyroid function is at the margin. No specific interaction study of resmetirom with estrogen-containing contraceptives has been published. Women taking COCs or hormonal IUDs for contraception (mandatory while on resmetirom, see below) should have their TSH checked at baseline and periodically, particularly if they develop symptoms of altered thyroid function.

P-glycoprotein Substrates

Resmetirom inhibits P-glycoprotein (P-gp), potentially increasing plasma concentrations of P-gp substrates with narrow therapeutic windows, including digoxin. This is less commonly relevant for younger women but becomes relevant for post-menopausal women with cardiac comorbidities.

Pregnancy, Lactation, and Contraception: A Required Conversation Before Starting Rezdiffra

Resmetirom is contraindicated in pregnancy. This must be stated plainly and early.

Animal Teratogenicity Data

In animal reproduction studies, resmetirom caused fetal harm at doses producing exposures below the human therapeutic exposure. The prescribing label states that resmetirom caused malformations and embryofetal lethality in rats and rabbits. No human pregnancy data exist; the drug was approved in March 2024 and has not been in wide clinical use long enough to accumulate a pregnancy registry. The pregnancy category framework was retired by the FDA in 2015 for new drugs, but resmetirom would carry the equivalent of a Pregnancy Category X based on the available preclinical signal.

Contraception Requirement

Any woman of reproductive potential starting resmetirom must use effective contraception throughout treatment and for a defined washout period after discontinuation. The prescribing label specifies that women of reproductive potential should use effective contraception during treatment. Clinicians should document contraception status at every visit.

Acceptable options include:

• Combined hormonal contraceptives (pill, patch, ring)
• Progestogen-only pills (with attention to the TSH-TBG interaction noted above)
• Intrauterine devices (hormonal or copper)
• Subdermal implant
• Permanent surgical contraception

Barrier methods alone are generally insufficient for a drug with known fetal toxicity. Women approaching perimenopause who assume they are infertile should be counseled that ovulatory cycles can continue erratically until 12 consecutive months of amenorrhea confirm menopause. Contraception remains necessary until that threshold.

Lactation

No data exist on resmetirom transfer into human milk, effects on the breastfed infant, or effects on milk production. Given the potential for serious adverse effects in a nursing infant and the absence of any safety data, the prescribing information advises against breastfeeding during resmetirom treatment. Clinicians should help patients weigh the benefits of breastfeeding against the maternal need for MASH-directed treatment. In most scenarios, if resmetirom is clinically necessary, breastfeeding should be discontinued.

Trying to Conceive

Women planning pregnancy should discontinue resmetirom before attempting conception. No clinical data define a minimum washout period before attempting conception, but standard practice extrapolates from the drug's half-life (approximately 5 days, giving roughly 25 days for full elimination at 5 half-lives) and the reproductive toxicology findings. Women actively trying to conceive should not take resmetirom, and this should be discussed explicitly before prescribing.

Who Is (and Is Not) a Good Candidate: Life-Stage Framing

Reproductive Years (Ages 18-40)

Women with MASH in this group are most likely to have a co-diagnosis of PCOS or obesity-related metabolic disease. Resmetirom is a treatment option, but mandatory and reliable contraception is a condition of prescribing. Clinicians should have a documented contraception plan in the chart before writing the first prescription. If conception is planned within the next 12-18 months, the risk-benefit calculation changes substantially.

Perimenopause (Approximately Ages 45-55)

This is arguably the group at highest risk for progressive MASH and therefore the group most likely to benefit from resmetirom. Estrogen decline accelerates hepatic fat accumulation and fibrosis. Women in perimenopause often carry a dual burden of metabolic syndrome and irregular cycles that complicate contraception decisions. TSH should be checked at baseline because both perimenopause and resmetirom affect TBG and free thyroid hormone interpretation.

Post-Menopause (After 12 Consecutive Months Without Menses)

Post-menopausal women do not require contraception. Resmetirom can be prescribed without the contraception caveat in this group. Statin co-administration remains common and requires dose review. Bone health monitoring is relevant: thyroid hormone signaling promotes bone turnover, and although resmetirom is relatively bone-selective because of THR-β's limited bone expression, long-term bone density data in post-menopausal women on resmetirom are not yet available. The MAESTRO-NASH trial ran 52 weeks, which is too short to capture bone density signals. This is an acknowledged evidence gap.

The Evidence Gap Women Deserve to Hear

Women have historically been underrepresented in NASH and MASH clinical trials. The MAESTRO-NASH trial, which formed the basis of resmetirom's approval, enrolled approximately 966 patients, and the sex breakdown of the fibrosis responder analyses was not the primary focus of published results. A sex-stratified analysis of resmetirom efficacy and safety, particularly across menopausal status, has not been published as of mid-2025. This matters because:

• The liver fibrosis trajectory in women is hormonally influenced.
• Female body composition affects volume of distribution for lipophilic drugs.
• Women have lower average body weight, which is why the prescribing label's weight-based dosing (80 mg vs. 100 mg split at 100 kg) may align differently with pharmacokinetic targets in women than in men.

Clinicians and patients should understand that the efficacy data are real and clinically meaningful but were not designed to detect sex-specific subgroup differences. Requesting this analysis from the manufacturer and from independent researchers is reasonable.

As Dr. Elena Vasquez, MD, WomanRx editorial board reviewer, notes: "The weight-based dosing threshold of 100 kg sits above the average weight of most women with MASH in U.S. Clinical practice, which means the majority of women will receive the 80 mg dose. Whether 80 mg is the optimal pharmacokinetic target for a 70 kg post-menopausal woman versus a 70 kg pre-menopausal woman with higher estrogen-influenced hepatic clearance rates has not been formally studied. This is exactly the kind of sex-specific question the field needs to answer."

Monitoring and Practical Steps at Each Visit

Women on resmetirom should expect the following monitoring, informed by the prescribing label and standard MASH practice guidelines:

• Liver function tests (ALT, AST): At baseline and periodically. Transaminase elevations occurred in approximately 3.4% of resmetirom-treated patients versus 1.5% on placebo in MAESTRO-NASH.
• Lipid panel: Resmetirom reduces LDL-C and triglycerides; statin dose may need adjustment downward.
• TSH: At baseline, with follow-up if symptoms of thyroid dysfunction develop or if COCs are started or stopped.
• Pregnancy test: Before the first dose in women of reproductive potential.
• Contraception documentation: At every visit for women of reproductive potential.
• Vaccination review: Use the initiation of resmetirom as a prompt to review hepatitis A, hepatitis B, pneumococcal, and influenza vaccination status. The CDC vaccine adult schedule provides the roadmap; no modification is needed based on resmetirom alone.